Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis

Journal of the Peripheral Nervous System

Volumn 19, Issue 3, 2014, Pages 192-196

  Sadjadi, Reza ^a   Reilly, Mary M ^b   Shy, Michael E ^c   Pareyson, Davide ^d   Laura, Matilde ^b   Murphy, Sinead ^e   Feely, Shawna M E ^c   Grider, Tiffany ^c   Bacon, Chelsea ^c   Piscosquito, Giuseppe ^d   Calabrese, Daniela ^d   Burns, Ted M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF IOWA   (United States)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Charcot Marie Tooth; Charcot Marie Tooth Neuropathy Score (CMTNS2) second version; outcome measures; psychometrics; Rasch analysis

Indexed keywords

ARTICLE; ASSESSMENT OF HUMANS; CHARCOT MARIE TOOTH NEUROPATHY SCORE SECOND VERSION; CONTROLLED STUDY; DISABLED PERSON; DISEASE SEVERITY; EVALUATION STUDY; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOMETRY; RASCH ANALYSIS; SCORING SYSTEM; CHARCOT-MARIE-TOOTH DISEASE; DEVICES; DISEASE COURSE; SEVERITY OF ILLNESS INDEX;

CHARCOT-MARIE-TOOTH DISEASE; DISEASE PROGRESSION; HUMANS; PSYCHOMETRICS; SEVERITY OF ILLNESS INDEX;

EID: 84921467941     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12084     Document Type: Article

References (15)

1. Bond TG, Fox CM, (2007). Applying the Rasch Model: Fundamental Measurement in the Human Sciences. Lawrence Erlbaum Associates Publishers. Mahwah.
2. Bren L, (2006). The importance of patient-reported outcomes...Its all about patients. FDA Consum 40: 26-32.
3. Campbell A, (1976). Subjective measures of well-being. Am Psychol 31: 117-124.
4. Cano SJ, Hobart JC, (2008). Watch out, watch out, the FDA are about. Dev Med Child Neurol 50: 408-409.
5. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T, (1999). Total neuropathy score: validation and reliability study. Neurology 53: 1660-1664.
6. Hobart JC, Cano SJ, Zajicek JP, Thompson AJ, (2007). Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 6: 1094-1105.
7. Lewis RA, McDermott MP, Herrmann DN, Hoke A, Clawson LL, Siskind C, Feely SM, Miller LJ, Barohn RJ, Smith P, Luebbe E, Wu X, Shy ME, (2013). High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 70: 981-987.
8. Murphy SM, Herrmann DN, McDermott MP, Scherer SS, Shy ME, Reilly MM, Pareyson D, (2011). Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 16: 191-198.
9. Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laura M, Radice D, Calabrese D, Hughes RA, Solari A,; CMT-TRIAAL; CMT-TRAUK groups (2011). Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 10: 320-328.
10. Rasch G, (1980). Probabilistic Models for Some Intelligence and Attainment Tests. University of Chicago Press, Chicago.
11. Reilly MM, Shy ME, Muntoni F, Pareyson D, (2010). 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord 20: 839-846.
12. Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, Li J, Lewis RA, Reilly M, (2005). Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64: 1209-1214.
13. Shy ME, Siskind C, Swan ER, Krajewski KM, Doherty T, Fuerst DR, Ainsworth PJ, Lewis RA, Scherer SS, Hahn AF, (2007). CMT1X phenotypes represent loss of GJB1 gene function. Neurology 68: 849-855.
14. Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, Herrmann D, Lewis RA, McDermott MP, (2008). Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 70: 378-383.
15. Skre H, (1974). Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 6: 98-118.